Sugi Predict

Sugi Predict / Compounds / SCHEMBL1965048

SCHEMBL1965048

SCHEMBL1965048

CCOC(=O)c1c(C)nc2cnccn12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.64
▸ ALDH1A1 P00352 6/20 0.56
▸ KDM4E B2RXH2 5/20 0.56
▸ HPGD P15428 4/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ KMT2A Q03164 1/20 0.50
▸ ALOX15 P16050 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ HCRTR1 O43613 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.48
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ GAA P10253 2/20 0.45
▸ CASP1 P29466 2/20 0.45
▸ CASP7 P55210 2/20 0.45
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15760438 0.86 MAPK1 (0.48) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20579817 0.81 CYP1A2 (0.74) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1965016 0.80 KMT2A (0.44) MAPK1ALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL7975453 0.80 KMT2A (0.59) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2829842 0.78 MAPK1 (1.00) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14739524 0.78 GAA (0.52) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18920834 0.78 ALDH1A1 (0.48) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1768201 0.77 RAB9A (0.69) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19717783 0.76 KDM4E (0.43) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL30856867 0.76 CYP1A2 (0.46) MAPK1ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 — — US disclosed
EP-2509424-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2012-10-17 — — EP disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 — — US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 — — US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 — — US disclosed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 — — WO disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 — — US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 — — US disclosed
US-7834039-B2 Oxadiazole compounds ABBOTT LABORATORIES (US) 2010-11-16 — — US disclosed
EP-2109364-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2009-10-21 — — EP disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 — — US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 — — US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 — — US disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 — — WO disclosed
WO-2008076356-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2008-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207704-A1 Novel Oxadiazole Compounds S1PR3, S1PR1, S1PR2 MAPK1 2258/4885ALDH1A1 4044/4885KDM4E 3611/4885
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP MAPK1 4069/4885ALDH1A1 344/4885KDM4E 2800/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP MAPK1 4389/4885ALDH1A1 312/4885KDM4E 2437/4885
US-20080280876-A1 Novel oxadiazole compounds S1PR3, S1PR1, S1PR2 MAPK1 2258/4885ALDH1A1 4044/4885KDM4E 3611/4885
US-20200102311-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP MAPK1 4069/4885ALDH1A1 344/4885KDM4E 2800/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP MAPK1 4389/4885ALDH1A1 312/4885KDM4E 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.